Maximum quantity allowed is 999
Please select the quantity
CAS RN: 89778-27-8 | Product Number: T2832
Toremifene Citrate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (Z)-4-Chloro-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate
- (Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine Citrate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
NT$5,000
|
20 | 2 | It can be shipped in about 3-4 weeks after ordering | |
| 5G |
NT$15,560
|
16 | 2 | It can be shipped in about 3-4 weeks after ordering |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | T2832 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__8ClNO·C__6H__8O__7 = 598.09 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 89778-27-8 |
| Related CAS RN | 89778-26-7 |
| Reaxys Registry Number | 8181005 |
| PubChem Substance ID | 160871014 |
| Merck Index (14) | 9550 |
| MDL Number | MFCD01729016 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
| Melting Point | 162 °C(dec.) |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
Transport Information:
| H.S.code* | 2921.49-000 |
Application
Biofilm research
Reference
- Repurposing Toremifene for Treatment of Oral Bacterial Infections
Application
Toremifene Citrate: A Selective Estrogen Receptor Modulator (SERM)
Toremifene citrate is a widely used nonsteroidal anti-estrogen agent for the treatment of hormone-dependent breast cancer. Toremifene is metabolized by cytochrome P450 (CYP450) enzymes into active metabolites N-desmethyltoremifene which has anti-estrogen activity as well. They act as an estrogen receptor antagonist in breast tissue. Tamoxifen is commonly referred to as a selective estrogen receptor modulator (SERM), since it behaves as an estrogen receptor agonist in other tissues. (The product is for research purpose only.)
References
- Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model
- Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
- Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
- Pharmacokinetics of selective estrogen receptor modulators (a review)
- Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance (a review)
Application
Studies on Materials for Controlled Release of Toremifene Citrate
References
- Silica xerogel as an implantable carrier for controlled drug delivery-evaluation of drug distribution and tissue effects after implantation
- Silica xerogel carrier material for controlled release of toremifene citrate
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.